Clinical Edge Journal Scan

Adjuvant radiotherapy less toxic in prone vs. supine position in BC patients with heavy breasts


 

Key clinical point: Adjuvant breast intensity-modulated radiotherapy (IMRT) in the prone vs. supine position was less toxic in women with large breast size and early-stage breast cancer (BC) who underwent breast-conserving surgery (BCS).

Major finding: IMRT in the supine vs. prone position was significantly associated with higher rates of desquamation anywhere in the breast and grade 3 desquamation in the overall cohort (odds ratio [OR] 1.78; P = .002, and OR 2.09; P < .001, respectively) and among women receiving extended fractionation (OR 1.92 and OR 2.76, respectively; both P < .001). The quality of life outcomes were similar between both treatment arms.

Study details: This phase 3 study included 357 women with large breast size and early-stage BC who underwent BCS and were randomly assigned to receive adjuvant IMRT in the supine or prone position.

Disclosures: This study was supported by Canadian Cancer Society. Dr. Rakovitch declared receiving grants and personal fees from some sources, and Dr. Pignol declared being employed by Accuray Inc.

Source: Vesprini D et al. Effect of supine vs prone breast radiotherapy on acute toxic effects of the skin among women with large breast size: A randomized clinical trial. JAMA Oncol. 2022 (May 26). Doi: 10.1001/jamaoncol.2022.1479

Recommended Reading

Neighborhood analysis links breast cancer outcomes to socioeconomic status
Breast Cancer ICYMI
‘Large benefit’ in ovarian function suppression for breast cancer
Breast Cancer ICYMI
Survival for elderly breast cancer patients 25% after 4 years
Breast Cancer ICYMI
Metastatic lobular, ductal cancers respond similarly
Breast Cancer ICYMI
This breast tumor subtype disproportionately affects Black women
Breast Cancer ICYMI
Breast cancer less common in Black women, so why do more die?
Breast Cancer ICYMI
Primary BC: Weekly vs. every-3-week nab-paclitaxel improves pCR but with higher toxicity
Breast Cancer ICYMI
Advanced TNBC: Camrelizumab + apatinib and eribulin shows promise in heavily pretreated patients
Breast Cancer ICYMI
Metformin disappoints in high-risk operable breast cancer
Breast Cancer ICYMI
Elacestrant prolongs survival in previously treated ER+/HER2− advanced BC
Breast Cancer ICYMI